Featured

Dr. Philip M Arlen to present at Festival of Biologics USA, San Diego, CA, April 23 – 24, 2025

Strattmont Group2025-04-18T12:18:23-04:00

Precision Biologics, Inc. CEO Philip M Arlen, MD will give the Keynote speech, and also...

Precision Biologics highlighted in GEN article, April 2025 issue

Strattmont Group2025-04-18T12:15:32-04:00

An article titled “Cancer Vaccines-Improving Their Aim” in the current April 2025 issue of trade...

Precision Biologics, Inc. to present at Antibody Therapeutics Xchange, April 15th, 2025, Philadelphia, PA

Strattmont Group2025-03-07T13:36:58-05:00

Precision Biologics announces that our Chief Scientific Officer, Kwong "Al" Tsang, will deliver a talk...

Precision Biologics, Inc. to present at AACR IO 2025, February 24, 2025, Los Angeles, CA

Strattmont Group2025-02-24T14:20:16-05:00

Precision Biologics announces that our Director of Research & Development, Massimo Fantini, PhD, will deliver...

Dr. Philip M Arlen to present at DDIP 2025, March 3-4, 2015, San Diego, CA

Strattmont Group2025-02-14T13:20:43-05:00

Precision Biologics, Inc. CEO, Philip M Arlen, MD, will participate on an interactive panel (Day...

Precision Biologics to Announce Development of New Monoclonal Antibody (mAb) PB-223 at SITC, Houston, TX, November 7-8, 2024

Strattmont Group2024-11-06T14:00:48-05:00

Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope...

Precision Biologics, Inc. to present recent data on the development of new monoclonal antibody (mAb) PB-223 at SITC 2024

Strattmont Group2024-11-04T11:13:35-05:00

Precision Biologics, Inc. will present novel data about affinity maturation and characterization of a novel...

Dr. Philip M. Arlen, CEO, to give opening keynote for Immuno US 2024 Conference, San Diego, CA, October 28th, 2024

Strattmont Group2024-10-22T14:37:59-04:00

DOWNLOAD 1

Precision Biologics, Inc. announces new US Patent filing on optimized antibody PB-233

Strattmont Group2024-09-24T12:26:59-04:00

Precision Biologics announces the filing of a new patent for our second asset, PB-233. This...

Precision Biologics announces publication of a new review article in Expert Review of Vaccines, September 1st, 2024.

Strattmont Group2024-09-09T11:34:10-04:00

Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...